Pieris

97 articles about Pieris

• Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential

  3/27/2024

  Pieris Pharmaceuticals, Inc. provided a corporate update announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin® protein immuno-oncology assets partnered with Pfizer, Boston Pharmaceuticals, and Servier.

• Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

  8/17/2023

  Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases and cancer, today announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals.

• Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring

  7/18/2023

  Pieris Pharmaceuticals, Inc. today provided a strategic update following recent events that have impacted its inhaled respiratory franchise, including AstraZeneca's discontinuation of enrollment of the Phase 2a study for elarekibep.

• Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study

  6/21/2023

  Pieris Pharmaceuticals, Inc. announced that partner AstraZeneca yesterday communicated to Pieris its decision to discontinue and cease dosing in the ongoing clinical studies of elarekibep.

• 

  AstraZeneca Halts Phase II Asthma Trial Due to Safety Findings in Toxicology Study

  6/21/2023

  Pieris Pharmaceuticals announced partner AstraZeneca’s decision to discontinue clinical studies of elarekibep, an inhaled IL-4 receptor alpha inhibitor, based on a non-clinical toxicology study.

• Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference

  5/22/2023

  Pieris Pharmaceuticals, Inc. announced the presentation of preclinical data from the Company's inhaled Jagged-1 targeting program, PRS-400, at the annual American Thoracic Society (ATS) International Conference being held in Washington, D.C. May 19-24, 2023.

• Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates

  5/10/2023

  Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, reported financial results for the quarter ended March 31, 2023, and provided a business update.

• Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)

  5/4/2023

  Pieris Pharmaceuticals, Inc. today announced the successful safety review of the 10 mg dry powder dose safety cohort from the ongoing multi-center, placebo-controlled phase 2a study of dry powder inhaler-formulated elarekibep (PRS-060/AZD1402).

• Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting

  4/17/2023

  Pieris Pharmaceuticals, Inc. announced the presentation of cinrebafusp alfa (PRS-343) clinical results from the Company's study in 2L+ HER2-positive gastric cancer at the American Association for Cancer Research annual meeting.

• Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates

  3/29/2023

  COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MARCH 29, 2023, AT 8:00 AM EDT.

• Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)

  1/10/2023

  Pieris Pharmaceuticals, Inc. today announced that the Company has achieved a $5 million milestone from Seagen.

• Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/2/2022

  Pieris Pharmaceuticals, Inc. reported financial results for the third quarter of 2022 ended September 30, 2022, and provided an update on the Company's recent and anticipated future developments.

• Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

  11/1/2022

  Pieris Pharmaceuticals, Inc. announced that the first subject has been dosed in the phase 1 study of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis and other forms of fibrotic lung disease.

• Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022

  10/26/2022

  Pieris Pharmaceuticals, Inc. today announced that it will host a third quarter 2022 investor call on Wednesday, November 2, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update.

• Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS

  8/24/2022

  Pieris Pharmaceuticals, Inc. today announced the presentation of preclinical data for PRS-400, an inhaled Jagged-1 Anticalin protein the Company is developing for the treatment of muco-obstructive lung diseases, at the European Respiratory International Congress 2022.

• Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/4/2022

  Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update.

• Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022

  7/28/2022

  Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2022 investor call on Thursday, August 4, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update.

• Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference

  6/2/2022

  Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 8:00 AM EDT.

• Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference

  5/18/2022

  Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 9:30 AM EDT.

• Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/11/2022

  Pieris Pharmaceuticals, Inc. reported financial results for the first quarter of 2022 ended March 31, 2022, and provided an update on the Company's future developments.